[Endolymphatic infusions in oncological patients].
Utilization of endolymphatic infusions against the background of the impaired barrier function of lymph nodes is inherent in a higher rate of tumor metastasization. The hazard increases in cases when tumore cells in the lymph system (especially in the thoracic duct) are in a free state, and substances dilating lymph vessels are employed. Therefore, endolymphatic infusions should be accomplished taking into account all the factors that could lower either directly or indirectly the barrier function of the lymphatic system.
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology; D003287:Contrast Media / Q000494:pharmacology; D004307:Dose-Response Relationship, Radiation; D004710:Endolymph; D006801:Humans; D007263:Infusions, Parenteral; D007761:Labyrinthine Fluids; D008196:Lymph / Q000528:radiation effects; D008198:Lymph Nodes / Q000187:drug effects / Q000528:radiation effects; D008207:Lymphatic Metastasis; D009369:Neoplasms / Q000628:therapy*; D011830:Radiation Effects; D011868:Radioisotopes / Q000627:therapeutic use; D012039:Regional Blood Flow; D013897:Thoracic Duct / Q000528:radiation effects
D000970:Antineoplastic Agents; D003287:Contrast Media; D011868:Radioisotopes
Ob éndolimfaticheskikh infuziiakh u onkologicheskikh bol'nykh